Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86UT8
UPID:
CATAC_HUMAN
Alternative names:
Coiled-coil domain-containing protein 84
Alternative UPACC:
Q86UT8
Background:
The Centrosomal AT-AC splicing factor, also known as Coiled-coil domain-containing protein 84, plays a crucial role in the minor spliceosome's function, specifically aiding in the splicing of rare minor intron subtypes. It acts as a negative regulator of centrosome duplication, ensuring proper cell division by controlling centriole numbers through the modulation of SASS6 protein degradation.
Therapeutic significance:
Given its involvement in Mosaic variegated aneuploidy syndrome 4, a disorder marked by severe developmental challenges and a high risk of malignancy, targeting the Centrosomal AT-AC splicing factor could offer new avenues for therapeutic intervention in cancer and developmental diseases.